Paladin Labs Obtains Canadian Approval for SEASONIQUE(R)

MONTREAL, CANADA, Apr 06 (MARKET WIRE) --
Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical
company, announced today that Health Canada has approved SEASONIQUE(R).
SEASONIQUE(R) is a next generation extended-cycle oral contraceptive for
the prevention of pregnancy. SEASONIQUE(R) is manufactured by Duramed
Pharmaceuticals, Inc., a wholly owned subsidiary of Teva Pharmaceutical
Industries Ltd. (NASDAQ: TEVA).

Under the SEASONIQUE(R) extended-cycle regimen, women take active tablets
of 0.15 mg levonorgestrel/0.03 mg of ethinyl estradiol for 84 consecutive
days, followed by seven days of a low dose of ethinyl estradiol (0.01
mg). The regimen is designed to reduce the number of withdrawal bleeding
periods from thirteen to four periods per year.

"The approval of SEASONIQUE(R) is great news for Canadian women. Now
women have an additional extended-cycle oral contraceptive from which to
reduce the number of menstruations from thirteen to four per year", said
Jonathan Ross Goodman, President & CEO Paladin Labs.

About Paladin Labs

Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty
pharmaceutical company focused on acquiring or in-licensing innovative
pharmaceutical products. With this strategy, a focused national sales
team and proven marketing expertise, Paladin has evolved into one of
Canada's leading specialty pharmaceutical companies. For more
information, please visit the Company's web site at www.paladinlabs.com

This news release contains forward-looking statements and predictions.
These forward-looking statements, by their nature, necessarily involve
risks and uncertainties that could cause actual results to differ
materially from those contemplated by the forward-looking statements. The
Companies consider the assumptions on which these forward-looking
statements are based to be reasonable at the time they were prepared, but
caution that these assumptions regarding the future events, many of which
are beyond the control of the Companies and their subsidiaries, may
ultimately prove to be incorrect. Factors and risks, which could cause
actual results to differ materially from current expectations, are
discussed in the annual reports, as well as in the Companies' Annual
Information Forms for the year ended December 31, 2009. The Companies
disclaim any intention or obligation to update or revise any
forward-looking statements whether a result of new information, future
events, or except as required by law. For additional information on risks
and uncertainties relating to these forward-looking statements, investors
should consult the Companies' ongoing quarterly filings, annual reports
and Annual Information Forms and other filings found on SEDAR at
www.sedar.com.

Contacts:
Paladin Labs Inc.
Samira Sakhia
Chief Financial Officer
514-669-5367
514-344-4675 (FAX)
info@paladinlabs.com
www.paladinlabs.com

Copyright 2010, Market Wire, All rights reserved.

-0-